# Takeshi Kato

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/takeshi-kato/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,337 |
| Field | Colorectal Cancer Treatments and Studies |
| h-index | 49 |
| i10-index | 149 |
| Last Known Institution | Osaka National Hospital |
| OpenAlex ID | https://openalex.org/A5100631065 |
| ORCID iD | 0000-0001-5347-550X |
| Works | 665 |

## Researcher papers

- [Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer](https://scholariq.org/papers/molecular-residual-disease-and-efficacy-of-adjuvant-chemotherapy-in-patients/)
- [Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies](https://scholariq.org/papers/clinical-utility-of-circulating-tumor-dna-sequencing-in-advanced/)
- [Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With <i>RAS</i> Wild-type, Left-Sided Metastatic Colorectal Cancer](https://scholariq.org/papers/panitumumab-vs-bevacizumab-added-to-standard-first-line-chemotherapy-and-overall/)
- [Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial](https://scholariq.org/papers/circulating-tumor-dna-guided-treatment-with-pertuzumab-plus-trastuzumab-for-her2/)
- [Highly sensitive assay for tyrosine hydroxylase activity by high-performance liquid chromatography](https://scholariq.org/papers/highly-sensitive-assay-for-tyrosine-hydroxylase-activity-by-high-performance/)
- [ctDNA-based molecular residual disease and survival in resectable colorectal cancer](https://scholariq.org/papers/ctdna-based-molecular-residual-disease-and-survival-in-resectable-colorectal/)
- [Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial](https://scholariq.org/papers/modified-xeliri-capecitabine-plus-irinotecan-versus-folfiri-leucovorin/)
- [Blood Perfusion Assessment by Indocyanine Green Fluorescence Imaging for Minimally Invasive Rectal Cancer Surgery (EssentiAL trial)](https://scholariq.org/papers/blood-perfusion-assessment-by-indocyanine-green-fluorescence-imaging-for/)
- [CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer](https://scholariq.org/papers/circulate-japan-circulating-tumor-dna-guided-adaptive-platform-trials-to-refine/)
- [Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial](https://scholariq.org/papers/trastuzumab-deruxtecan-in-patients-with-her2-positive-advanced-colorectal-cancer/)
- [Postoperative venous thromboembolism after surgery for locally recurrent rectal cancer](https://scholariq.org/papers/postoperative-venous-thromboembolism-after-surgery-for-locally-recurrent-rectal/)

## Researcher topics

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Colorectal Cancer Surgical Treatments](https://scholariq.org/topics/colorectal-cancer-surgical-treatments/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Genetic factors in colorectal cancer](https://scholariq.org/topics/genetic-factors-in-colorectal-cancer/)

## Researcher university

- [Osaka National Hospital](https://scholariq.org/institutions/osaka-national-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.